Neurocrine Biosciences, Inc. (nbix)

NBIX — Company Overview

Investors tracking NBIX follow a Drug Manufacturers - Specialty & Generic name listed on NMS within Healthcare.

NBIX — Business Description

The business profile of Neurocrine Biosciences, Inc. (NBIX) reflects its role in Drug Manufacturers - Specialty & Generic. Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of s…

Official website: https://www.neurocrine.com.

NBIX — Investment Thesis

Neurocrine Biosciences, Inc. (NBIX) attracts investors weighing Drug Manufacturers - Specialty & Generic fundamentals against current market pricing.

• Revenue is expanding at roughly 39.5% year-over-year (public data).
• Trailing P/E of 20.76× sits in a moderate band relative to high-growth peers.
• Forward P/E (11.65×) is below trailing P/E — earnings may be expected to improve.
• Equity market capitalization is approximately $14.18B.

See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.

NBIX — Financial Health

NBIX financial profile reflects operating efficiency and capital structure using available market fundamentals.

Profit margin of 20.9% indicates solid bottom-line conversion. Positive free cash flow of $638.24M supports balance-sheet flexibility.

NBIX — Growth Outlook

Growth outlook for Neurocrine Biosciences, Inc. (NBIX) depends on demand trends in Drug Manufacturers - Specialty & Generic and the company's ability to convert revenue into sustainable earnings.

• Revenue growth of 39.5% indicates strong top-line momentum.
• Earnings growth of 31.1% year-over-year supports improving profitability.
• Price is 25.1% below the 52-week high.
• Shares trade 14.2% above the 52-week low — limited rebound so far.

NBIX — Competitive Position

Neurocrine Biosciences, Inc. (NBIX) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.

• Competes within Healthcare, specifically in Drug Manufacturers - Specialty & Generic.
• Market capitalization of $14.18B places NBIX among large-cap peers.
• Gross margin near 64.5% may reflect pricing power or favorable mix.

NBIX — Summary

Neurocrine Biosciences, Inc. (NBIX) is a large-cap Healthcare company focused on Drug Manufacturers - Specialty & Generic, listed on NMS. Last price $139.49 with market cap $14.18B. Trailing P/E 20.76×. Revenue grew 39.5% year-over-year per public data. Notable strengths include revenue growth of 39.5% year-over-year. Key watch items include price 25% below the 52-week high — sustained negative sentiment. Review free estimates and earnings pages for NBIX; upgrade for institutional ownership and live headlines.